These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18258539)

  • 1. Effect of intravenous positive inotropic therapy on myocardial damage in patients with dilated cardiomyopathy.
    Albayrak F; Demircan S; Yazici M; Arslandağ M
    Anadolu Kardiyol Derg; 2008 Feb; 8(1):69. PubMed ID: 18258539
    [No Abstract]   [Full Text] [Related]  

  • 2. The long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease.
    Tsagalou EP; Anastasiou-Nana MI; Terrovitis JV; Nanas SN; Alexopoulos GP; Kanakakis J; Nanas JN
    Int J Cardiol; 2006 Apr; 108(2):244-50. PubMed ID: 16023232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination therapy; dobutamine and milrinone].
    Kato M; Hirayama A
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():428-33. PubMed ID: 22724242
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone.
    Guimond JG; Matuschak GM; Meyers F; Keating D
    Chest; 1986 Aug; 90(2):302-4. PubMed ID: 3731911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy.
    Sindone AP; Keogh AM; Macdonald PS; McCosker CJ; Kaan AF
    Am Heart J; 1997 Nov; 134(5 Pt 1):889-900. PubMed ID: 9398101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protocol-guide in clinical experimentation on inotropic drugs].
    Campolo L; Padrini R; Razzolini R; Klugmann S; Chioin R
    G Ital Cardiol; 1985 Jul; 15(7):695-9. PubMed ID: 4076703
    [No Abstract]   [Full Text] [Related]  

  • 8. Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy.
    Cripe LH; Barber BJ; Spicer RL; Wong BL; Weidner N; Benson DW; Markham LW
    Neuromuscul Disord; 2006 Nov; 16(11):745-8. PubMed ID: 17005398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is intermittent dobutamine treatment beneficial in patients with dilated cardiomyopathy?].
    Eryol NK; Güven M; Topsakal R; Abaci A; Başar E; Ergin A; Cetin S
    Anadolu Kardiyol Derg; 2002 Sep; 2(3):220-3. PubMed ID: 12223320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Congestive cardiomyopathy: basal hemodynamics and hemodynamics after various positive inotropic drugs administered singly or in combinations].
    Cappello C; Fusaro MT; Mattioli G
    Cardiologia; 1988 Dec; 33(12):1127-32. PubMed ID: 3076518
    [No Abstract]   [Full Text] [Related]  

  • 11. Dobutamine-related asthma in a patient awaiting cardiac transplantation: the eosinophilic dilemma.
    Aranda JM; Woo G; Pauly DF; Rodriguez E; Hill JA; Schofield RS
    J Heart Lung Transplant; 2004 Feb; 23(2):260-1. PubMed ID: 14761776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute and sustained hemodynamic effects of a new inotropic agent TA-064 (Denopamine) in patients with refractory heart failure with special reference to dose-response effects].
    Matsumoto N; Ito N; Kawagoe Y; Matsumura K; Honda T; Horie T; Takahashi S; Kimata S; Hirosawa K
    Kokyu To Junkan; 1986 Oct; 34(10):1113-20. PubMed ID: 3797842
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hemodynamic evaluation and SvO2 of inotropic drugs in ICU].
    Mandolfino T; Pedullà E; Praticò C; David A; Guzzo L; Mura M; Siracusano L; Sinardi AU
    Minerva Anestesiol; 1991 Oct; 57(10):934-5. PubMed ID: 1961559
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased ventricular contractility is not sufficient for effective positive inotropic intervention.
    Binkley PF; Van Fossen DB; Haas GJ; Leier CV
    Am J Physiol; 1996 Oct; 271(4 Pt 2):H1635-42. PubMed ID: 8897961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous inotropic agents in the intensive therapy unit: do they really make a difference?
    Opasich C; Russo A; Mingrone R; Zambelli M; Tavazzi L
    Eur J Heart Fail; 2000 Mar; 2(1):7-11. PubMed ID: 10742697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical care. Inotrope therapy.
    Place B
    Nurs Times; 1996 Aug 28-Sep 3; 92(35):55-7. PubMed ID: 8868896
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of inotropic agents in dilated cardiomyopathy].
    Gorb GD; Zhdaniuk IuI; Makovskaia TE; Tsybul'nik ZI
    Klin Med (Mosk); 1989 Jan; 67(1):87-90. PubMed ID: 2654468
    [No Abstract]   [Full Text] [Related]  

  • 18. Intermittent inotrope infusion for end stage heart failure in Duchenne muscular dystrophy.
    van Baalen A; von Spiczak S; Stephani U; Fischer G
    Neuromuscul Disord; 2008 Dec; 18(12):1005-6; author reply 1006. PubMed ID: 18952428
    [No Abstract]   [Full Text] [Related]  

  • 19. What Is Your Diagnosis? Dilated cardiomyopathy.
    Duchaussoy AC; Day J; Hughes D
    J Am Vet Med Assoc; 2015 Oct; 247(8):885-7. PubMed ID: 26421398
    [No Abstract]   [Full Text] [Related]  

  • 20. The cul-de-sac at the end of the road.
    Stevenson LW
    J Card Fail; 2003 Jun; 9(3):188-91. PubMed ID: 12815568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.